PKP2 and cardiac arrhythmia: At 4 weeks post gene deletion and 7 weeks post AAV treatment, human or mouse PKP2 inhibited the development of frequent PVCs and the occurrence of NSVT as summarized by a ventricular arrhythmia score (Fig. 4b, Supplementary Fig. 4, and Supplementary Table 1 used as an overall composite score estimating arrhythmia burden), prevented right ventricular remodeling (Fig. 4c), and prevented decline in left ventricular function (Fig. 4d).